<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02976350</url>
  </required_header>
  <id_info>
    <org_study_id>HormoneHFpEF001</org_study_id>
    <nct_id>NCT02976350</nct_id>
  </id_info>
  <brief_title>Hormone Deficiency in Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>MHDS in HFpEF</acronym>
  <official_title>Multiple Hormone Deficiency Syndrome in Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to describe the prevalence of Multiple Hormone Deficiencies in
      Heart Failure with preserved Ejection Fraction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the effectiveness of the neurohormonal model to explain the progression of heart
      failure and the many insights that it provided for the development of new therapies, there is
      increasing clinical evidence that suggests that our current models fail to completely explain
      the disease progression. Thus, neurohormonal models may be necessary but not sufficient to
      explain all aspects of disease progression in the failing heart. There is evidence suggesting
      that in heart failure there is a metabolic imbalance characterized by the predominance of the
      catabolic status over the anabolic drive.

      Consistent data coming from several independent groups have documented the reduced activity
      of most anabolic axes in HF with reduced ejection fraction. To date, no study has addressed
      the prevalence the presence and the prevalence of the Multiple Hormone Deficiencies in Heart
      Failure with preserved Ejection Fraction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Prevalence of Hormone deficiency</measure>
    <time_frame>1 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">35</enrollment>
  <condition>Heart Failure</condition>
  <condition>Hormone Deficiencies</condition>
  <arm_group>
    <arm_group_label>Patients with HFpEF</arm_group_label>
    <description>Male patients with heart failure with preserved ejection fraction</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum for determination of hormonal levels
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male patients with stable chronic heart failure with preserved ejection fraction
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients of affected by CHF, secondary to ischemic or idiopathic dilated
             cardiomyopathy

          -  left ventricle ejection fraction &gt; 50% or more

        Exclusion Criteria:

          -  severe liver disease

          -  serum creatinine levels &gt;2.5 mg/dl

          -  history of active cancer with life expectancy below 1 year acute coronary syndrome in
             the previous 6 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Cittadini, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antonio Cittadini</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Antonio Cittadini</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Heart failure with preserved ejection fraction</keyword>
  <keyword>GH deficiency</keyword>
  <keyword>Testosterone deficiency</keyword>
  <keyword>Low- T3 syndrome</keyword>
  <keyword>Multiple Hormone Deficiencies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

